1. Home
  2. ESPR vs GUT Comparison

ESPR vs GUT Comparison

Compare ESPR & GUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ESPR
  • GUT
  • Stock Information
  • Founded
  • ESPR 2008
  • GUT 1999
  • Country
  • ESPR United States
  • GUT United States
  • Employees
  • ESPR N/A
  • GUT N/A
  • Industry
  • ESPR Biotechnology: Pharmaceutical Preparations
  • GUT Trusts Except Educational Religious and Charitable
  • Sector
  • ESPR Health Care
  • GUT Finance
  • Exchange
  • ESPR Nasdaq
  • GUT Nasdaq
  • Market Cap
  • ESPR 445.6M
  • GUT 527.6M
  • IPO Year
  • ESPR 2013
  • GUT N/A
  • Fundamental
  • Price
  • ESPR $2.83
  • GUT $6.04
  • Analyst Decision
  • ESPR Buy
  • GUT
  • Analyst Count
  • ESPR 6
  • GUT 0
  • Target Price
  • ESPR $6.50
  • GUT N/A
  • AVG Volume (30 Days)
  • ESPR 6.1M
  • GUT 176.3K
  • Earning Date
  • ESPR 11-06-2025
  • GUT 01-01-0001
  • Dividend Yield
  • ESPR N/A
  • GUT 10.93%
  • EPS Growth
  • ESPR N/A
  • GUT N/A
  • EPS
  • ESPR N/A
  • GUT N/A
  • Revenue
  • ESPR $268,125,000.00
  • GUT N/A
  • Revenue This Year
  • ESPR $10.59
  • GUT N/A
  • Revenue Next Year
  • ESPR N/A
  • GUT N/A
  • P/E Ratio
  • ESPR N/A
  • GUT N/A
  • Revenue Growth
  • ESPR N/A
  • GUT N/A
  • 52 Week Low
  • ESPR $0.69
  • GUT $4.60
  • 52 Week High
  • ESPR $3.94
  • GUT $7.38
  • Technical
  • Relative Strength Index (RSI)
  • ESPR 78.99
  • GUT 56.14
  • Support Level
  • ESPR $2.37
  • GUT $5.95
  • Resistance Level
  • ESPR $2.73
  • GUT $6.03
  • Average True Range (ATR)
  • ESPR 0.16
  • GUT 0.06
  • MACD
  • ESPR 0.02
  • GUT 0.01
  • Stochastic Oscillator
  • ESPR 99.32
  • GUT 95.40

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

About GUT Gabelli Utility Trust (The)

Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.

Share on Social Networks: